Published on 10 May 2024 on Benzinga
ADMA Biologics Analysts Increase Their Forecasts After Upbeat Results - ADMA Biologics (NASDAQ:ADMA)
ADMA Biologics, Inc. ADMA reported better-than-expected first-quarter financial results and issued strong revenue guidance on Thursday.
ADMA Biologics posted GAAP earnings of 8 cents per share, beating market estimates of 5 cents per share. The company's quarterly sales came in at $81.875 million versus expectations of $77.275 million, according to data from Benzinga Pro.